US President Donald Trump has declared that imported generic medicines will be exempt from tariffs for two years starting from August 1, 2026. After this period, the tariffs will be set at 100% for a year and then rise to 200% as part of his strategy to relocate pharmaceutical production to the United States. This move allows foreign generic drug manufacturers a two-year window to establish production facilities in the US or face substantial tariffs on medicines exported to the American market.
In a social media post on Tuesday, Trump stated, “Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter.” This policy change could have significant implications for global pharmaceutical manufacturers supplying generic medicines to the US. However, Trump did not mention any specific countries or companies in his announcement and did not provide details on how the tariff system would be managed.
The new tariff structure introduced by Trump aims to incentivize drugmakers to invest in manufacturing facilities within the United States. Trump emphasized that the phased tariff approach is designed to encourage the reshoring of generic pharmaceutical production to America. He highlighted that companies failing to establish plants and equipment within the stipulated timeframe would face penalties. Trump’s ultimate goal with this policy is to safeguard the people of the United States.
According to the timeline outlined by the president, generic drug imports will continue to enter the US without tariffs for the initial two years following August 1. Subsequently, these imports will be subject to a 100% tariff for a year, followed by a 200% duty. Trump made a clear distinction between the tariff schedule for generic medicines and the existing policy for patented and branded drugs. He assured that the policy concerning patented, branded, or innovative drugs, which has been successful, will remain unchanged, without providing further specifics in the announcement.
Trump also mentioned that pharmaceutical companies are increasingly expanding their manufacturing presence throughout the United States. He highlighted the surge in the construction of pharmaceutical facilities across the country, emphasizing the unprecedented level of growth in this sector.
